Thermo Fisher Scientific CD133 (Prominin-1) Monoclonal Antibody (EMK08), FITC, eBioscience

Applications and Tested Dilution

Product Specifications

Product Specific Information

The EMK08 monoclonal antibody reacts with human CD133 (Prominin-1), a 120 kDa member of the pentaspan family of proteins, which also includes Prominin-2. Their expression is found within plasma membrane protrusions such as epithelial microvilli.
CD133 can exist in a number of alternatively spliced isoforms, and the protein has several N-linked glycosylation sites; the occurrence of both may be tissue-dependent.

Human CD133 was first identified as an epitope expressed on CD34+ hematopoietic progenitors. Although the ligand and function of CD133 remain unknown, it has proven to be very useful as a marker for both stem cells and cancer stem cells.
In addition to its expression on hematopoietic precursors, CD133 has been used to identify tumorigenic colon cancer stem cells, brain cancer stem cells, and prostate cancer stem cells, among others.

The binding of the EMK08 antibody does not block the binding of another anti-human CD133 antibody, TMP4 (Product # 12-1338-42), indicating that they recognize distinct epitopes.

This EMK08 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells.
Recommended usage: 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL.
Cell number should be determined empirically but can range from 10⁵ to 10⁸ cells/test.
Filtration: 0.2 µm post-manufacturing filtered.

Target Information

The CD133 (AC133) antigen is a 97 kDa glycoprotein with five transmembrane domains that appears as a 120 kDa band on protein gels due to glycosylation.
CD133 is a cell surface marker expressed by immature hematopoietic stem cells but not mature blood cells. It is also a marker for other stem and progenitor cells including neural and embryonic stem cells.

CD133 expression has been observed in certain cancers, including leukemias and brain tumors, possibly derived from stem cells. Low-level expression is also detected in kidney, pancreas, placenta, and fetal liver.
Mutations in this gene are associated with retinitis pigmentosa and Stargardt disease.
CD133 expression is regulated by at least five alternative promoters that are tissue-dependent, and multiple transcript variants encoding different isoforms have been identified.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

제품 이미지